Manipulation of NKG2D ligands by cytomegaloviruses: impact on innate and adaptive immune response by null Jonjic
REVIEW ARTICLE
published: 28 December 2011
doi: 10.3389/ﬁmmu.2011.00085
Manipulation of NKG2D ligands by cytomegaloviruses:
impact on innate and adaptive immune response
Irena Slavuljica, Astrid Krmpotic´ and Stipan Jonjic´*
Department of Histology and Embryology, Faculty of Medicine, University of Rijeka, Rijeka, Croatia
Edited by:
Linda F. Van Dyk, University of
Colorado Denver School of Medicine,
USA
Reviewed by:
Ofer Mandelboim, The Hebrew
University of Jerusalem, Israel
Klaus Früh, Oregon Health and
Science University, USA
*Correspondence:
Stipan Jonjic´, Department of
Histology and Embryology, Faculty of
Medicine, University of Rijeka, B.
Branchetta 20, 51 000 Rijeka, Croatia.
e-mail: jstipan@medri.hr
NKG2D is a potent activating receptor expressed on NK cells, NKT cells, γδ T cells, and
CD8T cells. NKG2D recognizes cell surface molecules structurally related to MHC class I
proteins induced by infection or other type of cellular stress. The engagement of NKG2D
leads to NK cell cytotoxicity and cytokine secretion or to a co-stimulation of CD8 T cells.
Both human and mouse cytomegalovirus (CMV) have evolved numerous mechanisms to
evade NKG2D-mediated immune response. This review describes the mechanisms used
by CMV to inhibit NKG2D ligand expression and the recent advances in exploiting the
NKG2D recognition pathway for mounting efﬁcient and long-lasting immune response.
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NK cells are lymphocytes of innate immunity which target virally
infected and tumor cells. Their activity is determined by a delicate
balance of signals from a sophisticated repertoire of inhibitory
and activating receptors expressed on their cell surface (reviewed
in Diefenbach and Raulet, 2001; Lanier, 2005). Inhibitory recep-
tors gauge the expression of MHC class I molecules, which are
constitutively expressed by healthy cells but may be downreg-
ulated under conditions of cellular stress. Therefore, inhibitory
receptors provide a mean for NK cells to exhibit cytotoxicity
toward infected or transformed cells via the “missing-self” axis. In
contrast, “induced-self” recognition involves the engagement of
various activating NK cell receptors by proteins expressed under
cellular stress, thus allowing the immune response to proceed.
One of the most potent activating receptors which mediate the
“induced-self” axis is NKG2D, a receptor shared by both the cells
of innate and adaptive immunity.
NKG2D RECEPTOR
NKG2D is a type-2 transmembrane glycoprotein expressed as a
disulﬁde linked homodimer on the cell surface (Diefenbach et al.,
2002; Jamieson et al., 2002). It is encoded by KLRK1 (killer cell
lectin-like receptor subfamily K, member 1), a single gene with
little polymorphism located on the mouse chromosome 6 and in
the syntenic position on human chromosome 12 (Houchins et al.,
1991). Inmice, alternative RNA splicing results in twoNKG2D iso-
forms – long (NKG2D-L) and short (NKG2D-S) – that differ in 13
amino acids (Diefenbach et al., 2002; Gilﬁllan et al., 2002). Resting
mouse NK cells express very little NKG2D-S, but its expression is
induced after NK cell activation. Neither isoform can be detected
in resting mouse CD8 T cells but after T cell receptor (TCR) stim-
ulation the expression of both isoforms is upregulated. Within its
intracellular domain NKG2D has no signaling motif but it asso-
ciates with signal-transducing proteins through charged residues
in the transmembrane region. The NKG2D-L isoform pairs with
the DAP10 signaling molecule, while NKG2D-S associates with
either DAP10 or DAP12. However, because CD8 T cells do not
express DAP12, the two NKG2D isoforms that are expressed by
activated T cells can interact with DAP10 only, whereas activated
NK cells can transmit signals through both DAP10 and DAP12
(Figure 1). The only isoform expressed in humans corresponds to
the long form in mouse and it interacts with DAP10 (Bauer et al.,
1999; Wu et al., 1999; Rosen et al., 2004).
NKG2D is expressed by all NK cells, most NKT cells, a subset
of γδ T cells, all human CD8 T cells, activated mouse CD8 T cells
and a subset of CD4 T cells (Bauer et al., 1999; Diefenbach et al.,
2000, 2002; Girardi et al., 2001; Jamieson et al., 2002; Ehrlich et al.,
2005). OnNK cells NKG2D serves as a primary activating receptor,
meaning that the engagement of NKG2D can override inhibitory
signals in the absence of the“missing-self” recognition (Cerwenka
et al., 2001; Figure 1). In addition to cytotoxicity, activation of NK
cells via NKG2D triggers the production of different cytokines,
including IFN-γ, TNF-α, and MIP-1β. Via this mechanism NK
cells are involved in the regulation of adaptive immunity. The
engagement of the NKG2D receptor on CD8 T cells is insufﬁcient
to generate aT cell response (Bauer et al., 1999; Ehrlich et al., 2005).
Instead,NKG2D acts as a co-stimulatory receptor which augments
TCR-induced responses (Groh et al., 2001; Maasho et al., 2005;
Markiewicz et al., 2005). The ability of NKG2D to co-stimulate T
cells may be determined by additional factors, such as the activa-
tion state of the T cells or the cellular environment (Roberts et al.,
2001; Meresse et al., 2004; Verneris et al., 2004).
NKG2D LIGANDS
NKG2D ligands are distantly related homologs of the MHC-I
proteins and are characterized by a striking structural diversity,
different expression patterns, and regulationmechanisms. Human
NKG2D ligands are MHC class-I-related protein A (MICA),
MICB, and UL16-binding proteins (ULBP1-6). MICA andMICB,
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FIGURE 1 | NKG2D acts as an activating and a co-stimulatory receptor.
NKG2D is a type-2 transmembrane homodimer that signals via association
with adapter molecules DAP10 or DAP12. Association with DAP12 leads to
phosphorylation of the ITAM and triggering of the Syk and/or Zap70 signaling
cascade. Association with DAP10 results in tyrosine phosphorylation on the
YINM motif and recruitment of the PI3K and Grb2 cascade. On NK cells,
NKG2D serves as an activation receptor, such that NKG2D engagement is
sufﬁcient to trigger NK cell-mediated cytotoxicity and cytokine production. In
contrast, NKG2D acts as a co-stimulatory receptor on CD8T cells, requiring
TCR-mediated signaling for their full activation. Grb2, growth factor
receptor-bound protein 2; IFN-γ, interferon γ; ITAM, immunoreceptor
tyrosine-based activating motif; PI3K, phosphoinositide 3-kinase; Syk, spleen
tyrosine kinase; TCR, T cell receptor; TNF-α, tumor necrosis factor α; Zap70,
zeta-chain associated protein kinase 70.
encoded by the genes within human MHC (Groh et al., 1996;
Bauer et al., 1999), are the only NKG2D ligands containing three
immunoglobulin-like domains (α1, α2, and α3), but unlike MHC
molecules, they do not associate with β2 microglobulin nor bind
antigenic peptides. All other NKG2D ligands are related toMHC-I
molecules but contain only α1 and α2 domains. Although named
by their ability to bind human CMV (HCMV) protein UL16, only
the ﬁrst two identiﬁed ULBP proteins ULBP1, ULBP2, and the
subsequently described ULBP6 bind this viral protein (Cosman
et al., 2001; Radosavljevic et al., 2002; Bacon et al., 2004; Eagle
et al., 2009). Like MIC proteins, ULBP5 and ULBP6 are trans-
membrane proteins, while proteins ULBP1-3 are anchored to the
membrane via glycosylphosphatidylinositol (GPI; Eleme et al.,
2004). ULBP family is also known as the retinoic acid early tran-
script 1 (RAET-1) family, since they show sequence homology to
the mouse retinoic acid early 1 (RAE-1) proteins (Nomura et al.,
1994;Cerwenka et al., 2000;Diefenbach et al., 2001). Fivemembers
of the RAE-1 family (RAE-1α–ε) are highly related to each other
(>85% amino acid homology) and differentially expressed in var-
ious mouse strains. A second family of mouse NKG2D ligands is
the H60 family that comprises three members H60 (a, b, and c) of
which H60a is a minor histocompatibility antigen (Malarkannan
et al., 1998; Takada et al., 2008;Whang et al., 2009). Finally,murine
UL16 protein-like transcript 1 (MULT-1) is the solemember of the
third family of mouse NKG2D ligands (Carayannopoulos et al.,
2002; Diefenbach et al., 2003).
NKG2D ligands are highly polymorphic, in particular MICA
and MICB for which 70 and 31 alleles with different afﬁnities for
NKG2D have been identiﬁed, respectively (Steinle et al., 2001).
There is also some degree of polymorphism in RAET-1 genes and
mouse H60 and RAE-1 genes (Eagle et al., 2006; Romphruk et al.,
2009). The reason for such a high degree of polymorphism is
unknown at the present but it may have evolved to counter the
selective pressure formed by pathogens and their evasion strate-
gies, in order to maintain a proper recognition of infected cells by
NK cells.
MOLECULAR MECHANISMS IN CONTROL OF NKG2D LIGAND
EXPRESSION
NKG2D ligand expression is induced by various stress conditions,
including cellular stress, malignant transformation or infection.
The exact mechanism by which this occurs is, however, mostly
unknown. NKG2D ligands are constitutively expressed on many
tumor cell lines and actively growing epithelial and hematological
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tumors (reviewed in Nausch and Cerwenka, 2008). The expres-
sion of NKG2D ligands makes tumors susceptible to killing by NK
cells in vitro and is associated with a decreased tumor progres-
sion and a decreased capacity to form metastases in vivo (Bauer
et al., 1999; Cerwenka et al., 2000, 2001; Diefenbach et al., 2000,
2001). NKG2D ligands are also induced on cells infected with
bacteria and viruses, including cells infected with cytomegalovirus
(CMV; Tieng et al., 2002; Siren et al., 2004; Vankayalapati et al.,
2005; Draghi et al., 2007; Ward et al., 2007, 2009; Fang et al.,
2008; Walsh et al., 2008). The control of NKG2D ligands expres-
sion includes both transcriptional and posttranscriptional mech-
anisms. The promoter regions of MIC genes contain heat shock
elements similar to those found in the HSP70 gene, which bind
heat shock factor-1 and induce MIC transcription in stressed cells
(Jinushi et al., 2003; Venkataraman et al., 2007). Similarly, the
retinoic acid-inducible element is mapped in the RAE-1γ pro-
moter thus suggesting that gene expression is directly regulated
by the retinoic acid (Nomura et al., 1994, 1996). Both human
and mouse cells upregulate NKG2D ligands following treatment
with DNA-damaging agents (Gasser et al., 2005) that activate a
major DNA damage pathway initiated by ATM (Ataxia telangiec-
tasia, mutated) or ATR (ATM- and Rad3-related) protein kinases
(Bartkova et al., 2005; Gorgoulis et al., 2005). Oncogenes, such as
the adenovirus E1A, induce transcription NKG2D ligands (Routes
et al., 2005). These ﬁndings are the proof that there is a link
between the constitutive activity of the DNA damage pathway and
oncogenes in tumors, and a frequent upregulation of NKG2D lig-
ands by transformed cells. Recent ﬁndings suggest that activation
of the phosphatidylinositol-3-kinase pathway induced by murine
CMV (MCMV) infection or tumor transformation is required
for the induction of the RAE-1 family of mouse NKG2D lig-
ands (Tokuyama et al., 2011). Finally, the expression of HCMV
immediate early gene (IE1 and IE2) displaces histone deacety-
lases and induces transcription of MIC proteins in infected cells
(Venkataraman et al., 2007).
Cytokines and toll-like receptor (TLR) signaling differentially
inﬂuence NKG2D ligand expression in different cell types and
environments. TGF-β downmodulates the expression of RAE-1
proteins, which might be one of the immune suppressive mecha-
nisms mediated by this cytokine (Routes et al., 2005; Eisele et al.,
2006). IFN-γ decreases the expression of MICA and ULBP2 on
melanoma and glioma cells, while IFN-γ and IFN-α selectively
downregulate H60a on sarcoma cell lines (Jinushi et al., 2003;
Schwinn et al., 2009). The downregulation of NKG2D ligands by
the proinﬂammatory cytokine IFN-γ may be unexpected, but, on
the other hand, it may represent amechanism to prevent sustained
triggering of the NKG2D receptor or, in the context of tumor
cells, a strategy to escape from immune surveillance. Furthermore,
IFN-γ-inducible small non-coding microRNAs (miRNAs) medi-
ate downregulation of MICA (Yadav et al., 2009). On the other
hand, the treatment of peritoneal macrophages or dendritic cells
(DC) with TLR agonists upregulates the transcription of ULBP
genes that may participate in the activation of NK and T cells
(Hamerman et al., 2004; Draghi et al., 2007; Ebihara et al., 2007;
Nedvetzki et al., 2007; Kloss et al., 2008).
In addition, various posttranscriptional mechanisms prevent
the expression of NKG2D ligands on healthy cells. Although
MICA and MICB genes are continuously transcribed, proteins
are not expressed on the cell surface because their translation
is held in check by cellular miRNAs. Cellular stress, such as a
heat shock or viral infection, induces MICA and MICB tran-
scription to levels that exceed the repressive ability of cellular
miRNAs and allow MIC proteins to be quickly expressed on
the cell surface (Stern-Ginossar et al., 2008b; Yadav et al., 2009).
In healthy cells, MULT-1 protein undergoes ubiquitination and
subsequent lysosomal degradation preventing its surface expres-
sion. In response to cellular stress, such as ultraviolet irradiation
or heat shock, ubiquitin-dependent degradation of MULT-1 is
reduced, leading to expression of MULT-1 protein at the cell sur-
face (Nice et al., 2009). Among other NKG2D ligands, MICA,
MICB, and ULBP5 are transmembrane proteins containing lysine
residues within their cytoplasmic tails and therefore might be reg-
ulated by ubiquitination as well. Collectively,multiple checkpoints
operating at different levels of NKG2D ligand synthesis facilitate
the expression of NKG2D ligands to a broad range of cellular
emergencies.
MANIPULATION OF NKG2D LIGAND EXPRESSION BY
CYTOMEGALOVIRUS
Infectionwith bothHCMVandMCMVupregulates the transcrip-
tion of NKG2D ligands,which can result inNKG2D-mediated lysis
of infected cells by NK cells. Viruses have developed different eva-
sive mechanisms to prevent the expression of NKG2D ligands on
the cell surface (Wilkinson et al., 2008; Figure 2). The HCMV
protein UL16 binds MICB, ULBP1, ULBP2, and ULBP6 in the
endoplasmatic reticulum (ER) and retains these ligands inside the
cell (Cosman et al., 2001; Dunn et al., 2003; Rolle et al., 2003;
Vales-Gomez et al., 2003; Welte et al., 2003; Wu et al., 2003). The
structure of UL16 revealed that this viral protein mimics a cen-
tral binding motif of otherwise structurally unrelated NKG2D,
thus enabling the virus to evade several diverse NKG2D ligands
(Muller et al., 2010). Another HCMV immunoevasin, UL142,
retains newly synthesized full-length MICA in the cis-Golgi com-
partment (Chalupny et al., 2006; Ashiru et al., 2009). Interestingly,
theMICA∗008 allele, which lacks the cytoplasmic domain, is resis-
tant to the action of UL142. Since MICA∗008 is frequently found
in humans, this suggests that during co-evolution HCMV exerts
selective pressure to the host and thus drives diversity and poly-
morphism of NKG2D ligands. In addition to targeting already
synthesized proteins, HCMV employs miRNAs to prevent the
translationof ligands forNKG2D.HCMVencodesmiRNA–UL112
that competes with endogenousmiRNA for binding to the 3′-UTR
(untranslated region) of the MICA transcript, thus repressing the
translation of this NKG2D ligand (Stern-Ginossar et al., 2007,
2008a).
Most wild-derived and laboratory mouse strains fail to con-
trol MCMV during the ﬁrst days post infection in spite of intact
NK cells expressing the NKG2D receptor. The explanation for
this phenomenon came with the discovery of MCMV inhibitors
that prevent the expression of NKG2D ligands on the surface of
infected cells (Figure 2). The deletion of one ormore of these viral
immunoevasins results in an attenuatedMCMVreplication in vivo
during early days post infection (Lenac et al., 2008; Figure 3).
However, if mice are depleted of NK cells or an NKG2D blocking
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FIGURE 2 | Major CMV inhibitors of NKG2D ligands. Both HCMV and
MCMV encode immunoevasins that inhibit expression of NKG2D ligands on
the surface of infected cells. (A)The HCMV protein UL16 inhibits MICB,
ULBP1, ULBP2, and ULBP6 expression by retaining them inside the cell.
UL142 prevents MICA expression via retention in the cis-Golgi
compartment. Certain alleles of MICA, such as MICA∗008, are resistant to
inhibition by HCMV due to truncation of the cytoplasmic domain. HCMV
microRNA (miR)–UL112 forms RISC complex that binds to the MICB
transcript and represses its translation. (B) MCMV encodes four
immunoevasins that redundantly downmodulate all mouse NKG2D ligands.
The m152 product retains RAE-1 family of proteins in ER/cis-Golgi
compartment. Not all RAE-1 proteins are equally susceptible to inhibition by
MCMV, namely RAE-1δ is more resistant than other RAE-1 proteins. The
m145 product interferes with MULT-1 expression by making it more
susceptible to the inhibition by the other immunoevasin, m138. The m155
product redirects H60 for lysosomal and/or proteasomal degradation.
Surface RAE-1ε, MULT-1, and H60 are additionally downmodulated by m138
which interferes with their recycling.
antibody is administered prior to the viral challenge, the replica-
tion of MCMV can be restored. gp40, encoded by m152 gene, was
the ﬁrst MCMV protein found to inhibit NKG2D. This ﬁnding
was unexpected, because m152 was known to be involved in the
maturation of MHC-I molecules and thus expected to enhance,
rather than inhibit, the NK cell response (Ziegler et al., 1997, 2000;
Krmpotic et al., 1999). The m152 protein targets RAE-1 ligands
for downregulation, thus promoting viral escape from NK cell
control (Lodoen et al., 2003; Arapovic et al., 2009). In this case,
a single viral gene product acts in evasion of both NK cell and
T cell antiviral immune responses. The m152 retains RAE-1 pro-
teins in the ERGIC/cis-Golgi compartment (Krmpotic et al., 2002;
Lodoen et al., 2003; Arapovic et al., 2009). However, not all RAE-
1 isoforms are equally susceptible to MCMV regulation. RAE-1δ
is more resistant to MCMV than other RAE-1 isoforms which
is, at least in part, due to the absence of the PLWY motif in the
RAE-1δ intracellular domain (Arapovic et al., 2009). Subsequent
studies have identiﬁed threemoreMCMVproteins involved in the
regulation of NKG2D ligands. The product of m155 gene down-
modulates the expression of H60 (Lodoen et al., 2004; Hasan
et al., 2005), although the underlying molecular mechanism is
not entirely understood. Lodoen et al. (2004) reported that H60
is degraded in MCMV-infected cells in a proteasome-dependent
pathway. Our results, however, show that the acquisition of endo-
b-N -acetylglucosaminodase H resistance and the half-life of the
protein are not affected by the virus, indicating that m155 affects
H60 after it leaves the ER (Hasan et al., 2005). The product of
the m145 gene binds MULT-1 after it leaves ER (Krmpotic et al.,
2005) and makes it more susceptible to another viral inhibitor.
Namely, MCMV proteins involved in downregulation of NKG2D
ligands are not restricted to m145 family; m138 gene product
also downmodulates MULT-1, as well as H60 (Lenac et al., 2006).
The m138 was originally described as a viral protein that binds
the Fc portion of immunoglobulin G and was designated as fcr-
1 (Thale et al., 1994). Since the deletion of this gene results in
viral attenuation in vivo, it was assumed that the attenuation is
caused by enhanced susceptibility of the virus to antibody depen-
dant cellular cytotoxicity. However, m138 deletion mutant virus
was also attenuated in B cell-deﬁcient mice, suggesting additional
function for this protein (Crnkovic-Mertens et al., 1998). A sub-
sequent study demonstrated that m138/fcr-1 targets MULT-1 and
H60 for internalization and thus contributes to viral resistance to
NK cell-mediated attack in vivo (Lenac et al., 2006). Likely, addi-
tional virus-encoded proteins or miRNAs that inhibit expression
of human and mouse NKG2D ligands will be discovered in the
future.
Despite so many immunoevasion strategies targeting NKG2D,
immunocompetent hosts succeed in the containment of CMV
infection. This raises the question of why would the virus evolve
such a robust immunosubversive potential if the host is able to
cope with primary infection. One of the possible explanations is
that NKG2D inhibitors, by facilitating virus escape from immune
surveillance, may ensure virus dissemination to various organs,
including the salivary glands, and aid in the horizontal virus
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FIGURE 3 | Insertion of NKG2D ligand RAE-1γ into the MCMV
genome overcomes viral immunoevasins of NK cells.To avoid lysis of
infected cell by the NK cells, MCMV encodes four immunoevasins
(m138, m145, m152, and m155) that downmodulate cell surface
expression of mouse NKG2D ligands. Consequently, blocking of NKG2D
has little or no effect on virus growth in vivo (upper part). Deletion of
either of NKG2D immunoevasins from the MCMV genome (e.g., m152)
results in the reconstitution of the surface expression of its respective
target and attenuated phenotype in vivo that can be restored by NKG2D
blocking (in the middle). Recombinant virus RAE-1γMCMV was
engineered by replacing m152 gene, whose product inhibits RAE-1
expression, with a cassette expressing RAE-1γ under HCMV immediate
early 1 promoter (IE-P). Infection with RAE-1γMCMV results in high
surface expression of cellular and virally encoded RAE-1γ (vRAE-1γ) and
profoundly attenuated phenotype in vivo (bottom part). PA,
polyadenylation sequence.
spread. Furthermore, by increasing the titer of the replicating
virus, the load of the latent viral genome could be increased, thus
representing an advantage for the virus to reactivate from latency
and spread.
THE ROLE OF NKG2D IN SHAPING VIRUS SPECIFIC CD8 T
CELL RESPONSE
In striking contrast to the well-deﬁned role of NK cells in con-
trol of early MCMV infection, very little is known regarding the
contribution of these innate effector cells in the regulation of a
speciﬁc immune response and long-term immunosurveillance of
viral infection.We previously investigated the contribution of spe-
ciﬁc lymphocyte subsets in the control of MCMV latency (Polic
et al., 1998). Recurrent infection was measured upon ablation of
CD4+ T cells, CD8+ T cells, and NK cells individually and in
combination. These studies revealed that control of CMV latency
and prevention of recurrent infection is organized in a redundant
and hierarchical fashion. Importantly, recurrence did not occur,
or occurred only rarely upon depletion of any individual sub-
set. However, depletion of NK cells led to a low (0–25%) or
high frequency (80–87%) of recurrence when performed in con-
junction with depletion of CD4+ or CD8+ T cells, respectively.
This study provides strong evidence demonstrating that innate
immune responses mediated by NK cells also operate in control of
latent MCMV infection, but the ultimate mechanism(s) involved
remained unsettled. Related to this, the role of viral evasion of NK
cells with regard to their role in control of chronic/latent infec-
tion remains largely undeﬁned. In addition, since some NK cell
receptors are also expressed on cells of speciﬁc immune responses,
the outcome of viral regulation of these receptors may also have
a direct role in shaping the quality of virus speciﬁc immune
response. For instance, NKG2D acts as a co-stimulatory receptor
on CD8 T cells (Groh et al., 2001; Maasho et al., 2005; Markiewicz
et al., 2005), which are primary effector cells in the resolution
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of a productive MCMV infection and establishment of latency
(Krmpotic et al., 2003). It is therefore feasible that viral inhibitors
of NKG2D ligands may have a direct impact on antiviral T cell
priming and effector functions.
To modify MCMV in a way that it overrides inhibitory signals
delivered to NK cells by self MHC-I molecules and potentiated
by viral immunoevasins, we have introduced an NKG2D lig-
and to the MCMV genome (Slavuljica et al., 2010). The ligand
employed was a member of the RAE-1 family, RAE-1γ, which
was inserted in place of its viral inhibitor m152 (Lodoen et al.,
2003; Krmpotic et al., 2005; Figure 3). The insertion of RAE-1γ
into the MCMV genome resulted in a recombinant virus with
profoundly attenuated phenotype in vivo, even in immunologi-
cally immature newborn mice and transgenic mice lacking type I
interferon receptor, as well as inmice immunologically suppressed
by total body γ-irradiation. Despite an attenuated phenotype,
the MCMV expressing the NKG2D ligand efﬁciently primed and
maintained an adaptive immune response, including the CD8
T cell response that was comparable to the one induced by the
wild-type MCMV (Figure 4). In addition, the adoptive transfer
of CD8+ T cells from mice vaccinated with MCMV express-
ing RAE-1γ to immunodepleted and infected host mice resulted
in the protection against CMV disease. Intriguingly, in a chal-
lenge infection,mice immunized withMCMV expressing RAE-1γ
FIGURE 4 | Potential mechanisms of amplified CD8T cell response
following RAE-1γMCMV infection. (A) Naive CD8T cells require
engagement of theTCR by MHC-I molecules presenting antigen along
with co-stimulatory signals, such as CD28 ligation by molecules of B7
family, to be fully activated.Wild-type MCMV (WT MCMV) dowmodulates
B7.1 and B7.2 from the surface of infected APCs resulting in compromised
T cell priming. Following RAE-1γMCMV infection co-stimulation via
RAE-1γ–NKG2D interaction may replace B7-CD28 interaction and allow
optimal CD8T cell priming. (B) Stochastic MCMV reactivation during
latency enables memory CD8T cells co-stimulation via NKG2D–RAE-1γ
interaction. Consequently, memory CD8T cells are maintained or even
inﬂated over time despite signiﬁcantly reduced viral DNA load. (C)
Challenge infection or any other serious stress leads to reactivation of
latent RAE-1γMCMV and enhanced virus speciﬁc T cell response as a
consequence of NKG2D ligand expression on cells undergoing virus
reactivation. (D) Despite profoundly attenuated replication in vivo and
reduced latent viral DNA load as compared to theWT MCMV,
RAE-1γMCMV efﬁciently primes and maintains virus speciﬁc CD8T cell
response. In a challenge infection, mice immunized with the
RAE-1γMCMV (red line triangle) resist salivary gland virus (SGV) challenge
better as compared to mice initially infected with theWT MCMV (gray line
triangle). APC, antigen presenting cell.
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resisted challenge with virulent salivary gland-derived MCMV,
with improved survival compared withmice initially infected with
wild-type MCMV, suggesting that expression of RAE-1γ in the
context of the MCMV infection provides an immune stimulus
that results in enhanced effectiveness of the adaptive immune
response.
What could be themechanism behind amore robust CD8T cell
response after the infection with a recombinant MCMV express-
ing the NKG2D ligand RAE-1γ instead of its viral inhibitor m152?
DCs can prime the CD8 T cell response in two ways; by direct pre-
sentation of endogenous peptides, or alternatively, exogenously
acquired antigens may be presented, this function known as cross-
presentation (Bevan, 2006). Although MCMV can infect DCs
(Andrews et al., 2001), thus providing viral peptides for direct
presentation, the majority of MCMV-speciﬁc CD8 T cells are not
directly primed (Snyder et al., 2010). It is a current belief that
viral immune evasion genes, which inhibit antigen presentation
and modulate the maturation and function of infected DCs, pro-
foundly impair direct priming of CD8T cells (Andrews et al., 2001;
Basta et al., 2002; Loewendorf et al., 2004;Munks et al., 2007; Bene-
dict et al., 2008). MCMV encodes three immunoevasion proteins
m04, m06, and m152 that interfere with MHC-I expression and
severely impair CD8 T cells recognition of infected cells (Pinto
and Hill, 2005; Lemmermann et al., 2011). Since m152 gene is
absent from the genome of MCMV expressing RAE-1γ, the den-
sity of antigen-MHC-I complexes on the surface of infected DCs
may be higher and therefore strengthen antigenic signals deliv-
ered to T cells. In T cells, co-stimulation is largely provided by
the interaction of CD28 and CD40L on the CD8 T cells with
B7 molecules and CD40 on the DCs, respectively. MCMV tar-
gets the co-stimulation signals by altering the ratio of positive and
negative co-signaling molecules on the DC surface. The MCMV
encoded m138, m147.5, and m155 downmodulate expression of
B7.1 (Loewendorf et al., 2004), B7.2 (Mintern et al., 2006), and
CD40 (Loewendorf et al., 2011), respectively, and therefore com-
promise T cell priming (Figure 4). Moreover, MCMV selectively
upregulates and retains inhibitory ligand PD-L1 on the surface of
infected DCs to ensure the induction of T cell anergy, tolerance, or
deletion (Benedict et al., 2008). Since co-stimulation of CD8T cells
by the NKG2D is in many ways similar to co-stimulation by the
CD28 molecule and leads to increased proliferation, cytotoxicity,
and cytokine response (Markiewicz et al., 2005), MCMV express-
ing RAE-1γ may tip the signaling balance of infected DCs toward
positive ones and thus promote T cell priming. It might be possi-
ble that the engagement of NKG2D on CD8 T cells by RAE-1γ on
infected DCs, and perhaps on other antigen presenting cells, pro-
vides a potent co-stimulatory signal during T cell priming able to
override viral immunoevasins and allow direct CD8T cell priming
to take place (Figure 4).
Cytokines, such as IL-2, IL-12, and IFN-α/β, stimulate CD8 T
expansion and differentiation and are required for optimal T cell
responses. Early in the course of an MCMV infection, IFN-α/β is
mainly produced by the activated plasmacytoidDCs (pDCs;Dalod
et al., 2002, 2003) and is critical for host survival (Presti et al.,
1998; Strobl et al., 2005). It mediates a number of immunoregu-
latory functions that vary depending upon the amount produced,
with high IFN-α/β levels promoting immune suppression (Biron,
2001; Theoﬁlopoulos et al., 2005). MCMV infection of BALB/c
mice induces a very high systemic production of IFN-α/β result-
ing in the ablation of CD8αDCs and delayed CD8 T cell responses
(Andrews et al., 2003; Robbins et al., 2007). In contrast, an efﬁcient
virus control by NK cells after infection with MCMV expressing
RAE-1γ decreases the intensity and the duration of pDC activa-
tion and limits the production of IFN-α/β (Slavuljica et al., 2010).
In this manner NK cells prevent cytokine-mediated loss of splenic
CD8α DCs and potentially promote T cell priming.
RAE-1γ–NKG2D co-signals may also positively regulate the
CD8 T cell response at later times after priming. The expan-
sion of the antiviral CD8 T cells in a latently infected host, also
known as “memory inﬂation,” is a feature of the immune response
to MCMV (Holtappels et al., 2002; Karrer et al., 2003). Based
on the detection of viral transcripts in tissue during latency, it
has been proposed that it is driven by the stochastic episodes
of reactivation of a limited number of viral genes (Reddehase
et al., 2008). In support of this, inﬂationary CD8 T cells dis-
play an effectormemory phenotype suggestive of repeated antigen
stimulation (Sierro et al., 2005; Munks et al., 2006). The accel-
erated clearance of productive infection with MCMV express-
ing RAE-1γ leading to a reduced latent viral genome load may
also reduce latency-associated viral transcription and compro-
mise “memory inﬂation” (Reddehase et al., 1994). However, the
number of antiviral CD8 T cells increases, rather than fades over
time, suggesting that the NKG2D co-stimulation may augment
TCR signal during latency and substitute for a reduced latent
viral genome load (Figure 4). Recently, it has been recognized
that NK cells can be long-lived and mount an antigen-speciﬁc
recall response (O’Leary et al., 2006; Cooper et al., 2009; Sun et al.,
2009; Paust et al., 2010). Whether or not infection with MCMV
expressing RAE-1γ induces memory NK cells to mount responses
during a subsequent encounter with MCMV remains merely a
speculation.
There is an urgent need to develop new therapeutic and pre-
ventive antiviral regimens, because at present no effective vaccine
for CMV is available. In this regard, the mouse model of infection
is currently the best system to experimentally deﬁne critical para-
meters affecting recurrent herpes virus infections. Both HCMV
and MCMV employed numerous strategies to downregulate the
expression of NKG2D ligands, pointing to the importance of
NKG2D signaling in virus surveillance. TheMCMV engineered to
express an NKG2D ligand shows an outstanding safety proﬁle, due
to improved innate immune clearance following inoculation, but
also because of being equally or evenmore immunogenic than the
wild-type MCMV, leading to a more efﬁcient adaptive immune
response. Therefore, it is possible that an approach like the one
described here might be used to generate an attenuated vaccine or
a CMV-based vaccine vector.
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